The frequency of how often you receive your therapy will be determined by both the specific therapy you are given and how long you have taken said therapy.

Elranatamab (BCMA-directed) is given as an injection once a week, but after twenty-four doses, the therapy can be given every two weeks instead of weekly.

For teclistamab (BCMA-directed), after the initial step-up dosing phase, the treatment is continued once weekly. If patients achieve a complete response for six months or more, they can be moved to a lower dose administered every other week.

With talquetamab (GPRC5D-directed), the physician and patient can choose whether a weekly or biweekly subcutaneous injection after the initial step-up dosing phase is appropriate.

This section will continue to be updated as more bispecific antibody therapies are approved.